Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Non-valvular Atrial Fibrillation

Treatments: Other: Non-interventional; Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03508258

CV185-664

Details and patient eligibility

About

Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs (Novel Oral Anticoagulants) in routine clinical practice in England

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of atrial fibrillation at or prior to index (the initiation of treatment)
• Incident prescription of an oral anticoagulant (index date)
• Patients with at least one year of computerized data prior to index date

Exclusion criteria

• Patients identified with a diagnosis of mechanical heart valve replacement or mitral stenosis identified at any point in the pre-index period in either CPRD by Read codes or in HES as ICD-10/OPCS codes
• Patients with indication of venous thromboembolism (pulmonary embolism or deep vein thrombosis) identified in in either CPRD by Read codes or HES by ICD-10/OPCS codes within 3 months prior to index

Other protocol defined inclusion/exclusion criteria could apply

Trial design

0 participants in 2 patient groups

Participants with NVAF starting Apixaban

Treatment:

Other: Non-interventional

Participants with NVAF starting Warfarin

Treatment:

Other: Non-Interventional